#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	5624	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2328	547.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1577	1577	C	720	C,A,G,T	600,3,3,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	5624	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2328	547.7	0	HET	.	.	.	C542T,G	.	542	542	C	935	935	C	709	C,T,G	391,164,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9204	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4189	502.7	0	.	n	.	0	T695C	SNP	695	695	T	1368	1368	C	677	C,A,G,T	547,3,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9204	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4189	502.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	2010	2010	A	670	A,C,G	573,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9204	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4189	502.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2644	2644	C	662	C,T,G,A	544,3,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9204	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4189	502.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3270	3270	T	568	T,C,G,A	475,2,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9204	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4189	502.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2718	2718	A	619	A	512	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	410	folP	855	855	100.0	folP.l15.c4.ctg.1	2007	49.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1356	1358	AGC	53;52;53	A;G;C	46;45;46	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	968	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3972	57.0	1	SNP	p	S91F	1	.	.	271	273	TTC	922	924	TTC	75;77;77	T;T;C,T	60;58;60,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	968	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3972	57.0	1	SNP	p	D95G	1	.	.	283	285	GGC	934	936	GGC	77;77;77	G;G;C,A,G	62;61;56,2,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	968	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3972	57.0	1	SNP	p	G95N	0	.	.	283	285	GGC	934	936	GGC	77;77;77	G;G;C,A,G	62;61;56,2,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	258	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1598	37.1	1	SNP	p	G45D	1	.	.	133	135	GAC	543	545	GAC	82;82;82	G;A;C	66;60;65	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	192	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1479	30.5	0	.	n	.	0	A197.	DEL	197	197	A	821	821	A	81	A	68	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1034	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3271	74.8	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	633	635	AAC	60;60;61	A;A;C,A	37;43;47,2	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1034	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3271	74.8	1	SNP	p	S87I	0	.	.	259	261	AGT	636	638	AGT	61;61;64	A,C;G;T,G	46,3;48;47,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1034	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3271	74.8	1	SNP	p	S87W	0	.	.	259	261	AGT	636	638	AGT	61;61;64	A,C;G;T,G	46,3;48;47,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1034	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3271	74.8	1	SNP	p	S87R	0	.	.	259	261	AGT	636	638	AGT	61;61;64	A,C;G;T,G	46,3;48;47,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1034	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3271	74.8	1	SNP	p	S88P	0	.	.	262	264	TCC	639	641	TCC	65;66;64	T;C,T;C	50;51,1;50	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	934	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3223	68.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1814	1816	GGC	54;54;54	G;G,A;C,T,A	46;46,1;44,1,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1540	1542	GCA	121;123;124	G;C;A	94;96;95	penA.13.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1543	1545	ATC	127;127;127	A;T;C,G,A	102;104;101,1,1	penA.13.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1555	1557	GTG	126;126;126	G;T;G	102;100;105	penA.13.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1555	1557	GTG	126;126;126	G;T;G	102;100;105	penA.13.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2059	2061	ACC	65;65;65	A,G,C;C;C	50,1,1;59;60	penA.13.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2113	2115	GTG	55;54;54	G;T,G,A;G	45;39,3,1;45	penA.13.001:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2113	2115	GTG	55;54;54	G;T,G,A;G	45;39,3,1;45	penA.13.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2236	2238	GGC	51;51;52	G;G;C,A,T	47;47;44,2,1	penA.13.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2245	2247	GGC	50;50;50	G;G;C,G	45;40;30,2	penA.13.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	874	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2616	74.5	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2263	2265	TCG	54;55;55	T,G;C,G;G	38,2;42,1;49	penA.13.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1154	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3545	72.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1745	1747	CCG	103;103;102	C,G,T;C,T;G,A,C	75,2,1;83,1;65,3,4	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	362	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1891	44.5	0	.	p	.	0	A17T	NONSYN	49	51	GCA	253	255	ACA	23;23;23	A;C;A	17;17;17	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	362	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1891	44.5	0	.	p	.	0	S22G	NONSYN	64	66	AGC	268	270	GGC	21;21;23	G;G;C	16;14;15	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	362	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1891	44.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	450	450	C	32	C	23	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	0	.	p	.	0	E48G	NONSYN	142	144	GAA	780	782	GGA	77;77;77	G;G;A	55;53;57	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	0	.	p	.	0	T87A	NONSYN	259	261	ACT	897	899	GCT	91;91;91	G,C;C;T,A,G	67,1;68;66,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	0	.	p	.	0	T89S	NONSYN	265	267	ACC	903	905	AGC	91;91;93	A;G,C;C	64;67,1;65	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	1065	1067	CAA	96;98;98	C;A;A	74;76;78	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1089	1091	GCA	85;84;84	G,C;C;A	67,1;68;68	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	1197	1199	CAA	68;68;68	C;A;A	53;52;53	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	0	.	p	.	0	N189S	NONSYN	565	567	AAC	1203	1205	AGC	65;65;64	A;G;C	50;50;49	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	0	.	p	.	0	Y212fs	FSHIFT	634	634	T	1272	1272	T	56	T,G	41,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	1	SNP	p	G120K	1	.	.	358	360	AAG	996	998	AAG	91;91;90	A;A;G	77;77;77	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	1	SNP	p	A121D	1	.	.	361	363	GAC	999	1001	GAC	94;94;93	G;A,G;C,A	80;77,1;75,1	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	476	porB1b	1041	1041	98.08	porB1b.l15.c4.ctg.1	2264	46.0	1	SNP	p	D121N	0	.	.	361	363	GAC	999	1001	GAC	94;94;93	G;A,G;C,A	80;77,1;75,1	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2822	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4970	131.5	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1971	1973	AAT	166;165;165	A;A;T,G	141;142;141,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	304	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1282	56.5	1	SNP	p	V57M	1	.	.	169	171	ATG	700	702	ATG	107;106;106	A;T;G	89;89;89	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
